Citigroup
TSHA icon

Citigroup’s Taysha Gene Therapies TSHA Stock Holding History

Citigroup’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.09M Buy
306,907
+249,827
+438% +$1.48M ﹤0.01% 2896
2026
Q1 		$255K Sell
57,080
-5,935
-9% -$27.6K ﹤0.01% 3889
2025
Q4 		$347K Buy
63,015
+29,520
+88% +$143K ﹤0.01% 3747
2025
Q3 		$110K Sell
33,495
-96,822
-74% -$274K ﹤0.01% 4234
2025
Q2 		$301K Sell
130,317
-2,877
-2% -$6.25K ﹤0.01% 3872
2025
Q1 		$185K Sell
133,194
-120,098
-47% -$201K ﹤0.01% 4248
2024
Q4 		$438K Buy
253,292
+120,680
+91% +$250K ﹤0.01% 3923
2024
Q3 		$267K Buy
132,612
+88,677
+202% +$195K ﹤0.01% 4148
2024
Q2 		$98.4K Sell
43,935
-211,268
-83% -$615K ﹤0.01% 4221
2024
Q1 		$732K Sell
255,203
-55,760
-18% -$116K ﹤0.01% 3276
2023
Q4 		$550K Buy
310,963
+29,844
+11% +$59.5K ﹤0.01% 3336
2023
Q3 		$888K Buy
+281,119
New +$525K ﹤0.01% 2610
2022
Q4 		– Sell
-635
Closed -$1K – 5959
2022
Q3 		$1K Sell
635
-523
-45% -$1.9K ﹤0.01% 5695
2022
Q2 		$4K Sell
1,158
-9,158
-89% -$36.3K ﹤0.01% 5718
2022
Q1 		$67K Sell
10,316
-291
-3% -$2.17K ﹤0.01% 4608
2021
Q4 		$124K Buy
10,607
+7,286
+219% +$110K ﹤0.01% 4624
2021
Q3 		$62K Buy
3,321
+1,950
+142% +$37.1K ﹤0.01% 4630
2021
Q2 		$29K Buy
1,371
+795
+138% +$18.3K ﹤0.01% 5107
2021
Q1 		$12K Sell
576
-1,038
-64% -$28.1K ﹤0.01% 5559
2020
Q4 		$43K Buy
+1,614
New +$34.8K ﹤0.01% 6152

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citigroup's TSHA Position: Q2 2026 in Review

Citigroup increased its Taysha Gene Therapies (TSHA) stake by 438% in Q2 2026, buying an estimated $1.48M and bringing the position to 306,907 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2896.

Citigroup first reported a position in TSHA in Q4 2020 and has held it in 20 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Citigroup held 306,907 shares of Taysha Gene Therapies worth $2.09M as of Q2 2026.
  • Citigroup bought 249,827 Taysha Gene Therapies shares in Q2 2026, an estimated $1.48M.
  • Taysha Gene Therapies made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2896 holding.
  • Citigroup first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 20 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.